Amgen Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar in Advanced Melanoma
Key Insights
Amgen's Phase 3 study (NCT05907122) for ABP 206, a biosimilar candidate for Opdivo (nivolumab), has officially reached completed status as of February 27, 2026.
The trial enrolled 256 subjects with resected stage III or IV melanoma (search) to demonstrate pharmacokinetic similarity and clinical efficacy over a 12-month adjuvant treatment period.
Data analysis is currently underway to support regulatory filings, with potential to establish Amgen as a key provider of lower-cost immunotherapy for advanced melanoma (search) patients.
Amgen has successfully completed its Phase 3 clinical trial for ABP 206, a biosimilar candidate targeting Opdivo (nivolumab), marking a significant milestone in the company's efforts to provide more affordable immunotherapy options for advanced melanoma (search) patients. The study (NCT05907122) officially reached completed status on February 27, 2026, with data analysis now underway to support regulatory submissions.
Trial Design and Patient Population
The Phase 3 study enrolled 256 subjects diagnosed with resected stage III or IV melanoma (search), focusing on demonstrating both pharmacokinetic similarity and clinical efficacy compared to the reference product Opdivo. The trial was designed as a 12-month adjuvant treatment study, with primary completion achieved in March 2025 and final updates posted in late February 2026.
The study's completion represents a crucial step toward potentially expanding access to checkpoint inhibitor therapy for melanoma (search) patients, as biosimilars typically offer treatment options at reduced costs compared to originator biologics.
Regulatory and Commercial Implications
With the trial now complete, Amgen is analyzing the data to support regulatory filings for ABP 206. If successful in demonstrating biosimilarity to Opdivo, ABP 206 could position Amgen as a key provider of lower-cost immunotherapy for advanced melanoma (search) treatment.
The completion of this Phase 3 program has already influenced investor sentiment, with Wells Fargo (search) raising Amgen's price target from $325 to $375 on February 19, 2026, while maintaining an Equal Weight rating. The firm specifically noted that it was assigning new price targets to reflect the additional value of Phase 3 pipeline assets, including this biosimilar program.
Market Context
Opdivo (nivolumab) is a widely used PD-1 (search) checkpoint inhibitor that has become a standard of care in various oncology indications, including melanoma (search). The development of biosimilar versions could significantly impact treatment accessibility and healthcare costs, particularly for patients requiring extended adjuvant therapy periods.
Amgen, founded in 1980 and headquartered in California, has established itself as a leading global biotechnology company focused on discovering, developing, and manufacturing innovative human therapeutics for serious illnesses. The successful completion of the ABP 206 Phase 3 trial adds to the company's growing portfolio of biosimilar candidates and reinforces its commitment to expanding patient access to critical cancer treatments.